CinCor Pharma, Inc. (CINC)

29.06 0.00 (0.00%) At close: 05:00PM EDT

CinCor Pharma, Inc.

City Point
6th Floor 230 Third Avenue
Waltham, MA 02451
United States
844 531 1834
https://www.cincor.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 19

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Marc M. P. de Garidel	CEO & Director	776.86k	N/A	1958
Dr. Mason W. Freeman M.D.	Chief Medical Officer	285.56k	N/A	1951
Ms. Catherine Pearce DHSc, M.B.A., MBA	Co-Founder & COO	N/A	N/A	1976
Mr. Michael W. Kalb CPA	Exec. VP, CFO & Principal Accounting Officer	N/A	N/A	1971
Ms. Ida Hatoum	Sr. VP and Head of People, Talent & Culture	N/A	N/A	N/A
Hema Keshava	Corp. Controller	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

Corporate Governance

CinCor Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.